Modality
Radioligand
MOA
ALKi
Target
PRMT5
Pathway
Incretin
EpilepsyEwing Sarcoma
Development Pipeline
Preclinical
~Jan 2019
→ ~Apr 2020
Phase 1
~Jul 2020
→ ~Oct 2021
Phase 2
~Jan 2022
→ ~Apr 2023
Phase 3
Jul 2023
→ Dec 2031
Phase 3Current
NCT03109304
2,746 pts·Epilepsy
2023-07→2028-04·Active
NCT04285528
871 pts·Ewing Sarcoma
2023-09→2031-12·Not yet recruiting
3,617 total pts2 indications
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2028-04-112.0y awayPh3 Readout· Epilepsy
2031-12-265.7y awayPh3 Readout· Ewing Sarcoma
Trial Timeline
Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P3
Active
P3
Not yet…
Catalysts
Ph3 Readout
2028-04-11 · 2.0y away
Epilepsy
Ph3 Readout
2031-12-26 · 5.7y away
Ewing Sarcoma
ActiveNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03109304 | Phase 3 | Epilepsy | Active | 2746 | BodyWt |
| NCT04285528 | Phase 3 | Ewing Sarcoma | Not yet recr... | 871 | EFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Miriosocimab | Pfizer | Phase 1 | PARP | |
| Nirarelsin | Johnson & Johnson | Phase 2 | PRMT5 | |
| MRK-7739 | Merck & Co | Preclinical | IL-23 | |
| MRK-853 | Merck & Co | Phase 1 | PRMT5 | |
| BMY-2495 | Bristol-Myers Squibb | Phase 3 | KRASG12D | |
| Geliderotide | Sanofi | Phase 1/2 | PRMT5 | |
| Capifutibatinib | Sanofi | Approved | PRMT5 | |
| NVO-9615 | Novo Nordisk | Phase 2/3 | PRMT5 | |
| Suracagene | GSK | Phase 3 | PRMT5 | |
| DSN-5254 | Daiichi Sankyo | Phase 1 | B7-H3 |